Case Report
J Rheum Dis 2013; 20(6): 361-363
Published online December 30, 2013
© Korean College of Rheumatology
A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis
Correspondence to : Seung-Hoon Baek
Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFα) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFα agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFα agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
Keywords Ankylosing spondylitis, End-stage renal disease, Peritoneal dialysis, Tumor necrosis factor-alpha
PDF
Standard view
Export citation
Share Article
Case Report
J Rheum Dis 2013; 20(6): 361-363
Published online December 30, 2013
Copyright © Korean College of Rheumatology.
A Case of Etanercept Treatment in a Patient with Ankylosing Spondylitis on Peritoneal Dialysis
Sang-A Choi1, Seung-Geun Lee1, Sang-Heon Song1, Ji-Min Kim1, Hye-Yoon Jang1, Woo-Jin Jung1, Jong-Hyun Choi1, Young-Eun Park2, Seong-Hu Park3, Joung-Wook Lee4, Jun-Hee Lee5, Seung-Hoon Baek5, Geun-Tae Kim6
Department of Internal Medicine, Pusan National University School of Medicine1, Busan, Malgeunsem Hospital2, Changwon, Young-do Hospital3, Busan St. Mary’s Medical Center4, Division of Rheumatology, Department of Internal Medicine, Ilsin Christian Hospital5, Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine6, Busan, Korea
Correspondence to:Seung-Hoon Baek
Abstract
Treatments for patient with ankylosing spondylitis (AS) include non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs) and anti-tumor necrosis factor-alpha (TNFα) agents. However, owing to the well-known nephrotoxicity of NSAIDs and some DMARDs, the use of these drugs is limited in AS patients with renal insufficiency. As the pharmacokinetics and metabolism of anti-TNFα agents in patients of end stage renal disease, especially those receiving peritoneal dialysis (PD), have not been investigated well, little is known about treating them with anti-TNFα agents. We described the safety and efficacy of etanercept, a soluble fusion protein comprising the TNF receptor 2 in linkage with the Fc portion of immunoglobulin G, in a 40-year-old male AS patient receiving PD.
Keywords: Ankylosing spondylitis, End-stage renal disease, Peritoneal dialysis, Tumor necrosis factor-alpha
Article Tools
Stats or Metrics
Share this article on
Related articles in JRD
-
Osteopoikilosis in a young ankylosing spondylitis patient
Vitaly Omelchenko, M.D., Elena Letyagina, M.D., Maxim Korolev, M.D.
J Rheum Dis 2024; 31(4): 253-256 -
Machine learning models with time-series clinical features to predict radiographic progression in patients with ankylosing spondylitis
Bon San Koo, M.D., Ph.D., Miso Jang, M.D., Ph.D., Ji Seon Oh, M.D., Ph.D., Keewon Shin, Ph.D., Seunghun Lee, M.D., Ph.D., Kyung Bin Joo, M.D., Ph.D., Namkug Kim, Ph.D., Tae-Hwan Kim, M.D., Ph.D.
J Rheum Dis 2024; 31(2): 97-107 -
Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis
Inbeom Kwon, M.D., Nayeon Choi, M.S., Ji Hui Shin, M.S., Seunghun Lee, M.D., Ph.D., Bora Nam, M.D.,Ph.D., Tae-Hwan Kim, M.D., Ph.D.
J Rheum Dis 2024; 31(1): 41-48
